Mergers and Acquisitions - Cixing Co., Ltd. plans to acquire 75% of Shenyang Shunyi Technology Co., Ltd. through a combination of issuing shares and cash payments, while also raising supporting funds from no more than 35 qualified investors [1] - United Optoelectronics intends to purchase 100% of Changyi Optoelectronics from 12 shareholders via share issuance and will also raise supporting funds [2] - Inte Group's subsidiary, Inte Pharmaceutical, successfully acquired 100% equity of Zhejiang Huadong Pharmaceutical Group Co., Ltd. for 369 million yuan and signed a transaction contract with the transferor [3] Shareholding Changes - Guokang Biochemical announced that shareholders plan to collectively reduce their holdings by no more than 6% of the company's total shares, with specific plans from two major shareholders to reduce by 3% each [4] - Ruilian New Materials reported that a major shareholder, Guofu Yongyu, plans to reduce its holdings by up to 3.33%, equivalent to 573,110 shares [5] - Hongxin Technology disclosed that two major shareholders, Baiqiang and Taizhou Qixin, plan to reduce their holdings by 2.62% and 2.12% respectively [6] Risk Matters - Sinovac Biotech highlighted the high-tech, high-risk, and high-value characteristics of its innovative drugs, emphasizing the uncertainties involved in the research and approval processes [7] - Zhongheng Design noted that the revenue from its low-altitude economy and commercial aerospace projects is minimal compared to its consolidated financial statements, despite winning several contracts in these sectors [8] Restructuring - *ST Xinyan announced that it received a notice from a creditor applying for the company's restructuring and pre-restructuring procedures [10]

Core Insights - Weikang Pharmaceutical (维康药业) has been recognized for its strong R&D capabilities and excellent products in the traditional Chinese medicine industry, receiving the "2025 Hongding List VIP Cooperation Enterprise" award at the 2025 Health Industry Pharmaceutical Conference [1] - The company's flagship product, Yinhuang Diban (银黄滴丸), has been included in the "Top 10,000+ Pharmacy Star Products" list, highlighting its market acceptance and clinical efficacy [1] - Weikang is focusing on the secondary development of Yinhuang Diban, with a Phase II clinical trial for recurrent oral ulcers successfully completed and discussions for Phase III trials ongoing [1] Product Development - Yinhuang Diban is composed of honeysuckle and Scutellaria baicalensis extracts, known for its safety and effectiveness in treating various throat and respiratory conditions [1] - The product has received multiple industry accolades, including the top position in the "China Pharmaceutical Brand List" for adult cold medications and a prestigious patent award [1] - The company is also developing a second growth engine centered around broken-spore Ganoderma lucidum powder, leveraging its production advantages from the "Hometown of Chinese Ganoderma" in Longquan, Zhejiang [4] Market Strategy - Weikang is implementing a dual-channel strategy, optimizing both online and offline sales channels, including e-commerce platforms and health product counters [4] - The company plans to expand its product line to include high-value items such as Ganoderma lucidum oil and slices, aiming to tap into the market potential of the Ganoderma series [4] - The company’s mission of "Maintaining Life, Committed to Health" drives its continuous R&D efforts and deepens its presence in the traditional Chinese medicine health sector [4] Future Outlook - The company is expected to enhance its market competitiveness through R&D innovation, technological upgrades, and channel optimization in the growing traditional Chinese medicine health industry [5] - With the iterative upgrades of core products and accelerated commercialization of new products, Weikang is poised to expand its market share and strengthen its profit growth drivers [5]

证券代码：300878 证券简称：维康药业 公告编号：2025-024 浙江维康药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、浙江维康药业股份有限公司（以下简称"公司"）回购专用证券账户中 的股份 2,739,026 股不参与本次权益分派。公司 2024 年年度权益分派方案为：以 公司现有总股本 144,790,322 股剔除已回购股份 2,739,026 股后的 142,051,296 股 为基数，向全体股东每 10 股派 1.40 元（含税）人民币，实际派发现金分红总额 为 19,887,181.44 元（含税）人民币。 2、本次权益分派实施后，按公司总股本（含回购股份）144,790,322 股折算 的每 10 股现金分红金额以及据此计算的除权除息参考价的相关参数和公式计算 如下： 按总股本（含回购股份）折算的每 10 股现金红利（含税）=现金分红总额/ 总股本*10 股=19,887,181.44/144,790,322*10=1.373515 元（保留六位小数，最后 一位直接截取， ...

浙江维康药业股份有限公司 2024 年度股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 浙江天册律师事务所 关于 法律意见书 浙江天册律师事务所 关于浙江维康药业股份有限公司 2024 年度股东大会的 法律意见书 编号：TCYJS2025H0793 号 致：浙江维康药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江维康药业股份有限公司（以 下简称"维康药业"或"公司"）的委托，指派本所律师参加公司 2024 年度股东 大会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人 民共和国公司法》（以下简称"《公司法》"）和《上市公司股东会规则》（以下 简称"《股东会规则》"）等法律、法规和有关规范性文件，以及《浙江维康药业 股份有限公司章程》（以下简称"《公司章程》"）的有关规定，出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会召集、召开程序、出席人员的 资格、召集人的资格、表决程序及表决结果的合法有效性发表意见，不对会议所审 议的议案内容和该等议案中所表 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-023 浙江维康药业股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 4、股东大会的召集人：公司董事会。 5、主持人：董事长刘洋先生。 6、本次股东大会的召集、召开符合《中华人民共和国公司法》、《上市公司 股东大会规则》、《深圳证券交易所创业板股票上市规则》等有关法律、行政法 规、部门规章、规范性文件及《公司章程》等有关规定。 （二）会议出席情况 1、股东总体出席情况 （一）会议召开情况 1、会议时间 （1）现场会议时间：2025年5月20日（星期二）下午14:00 （2）网络投票时间：2025年5月20日。其中，通过深圳证券交易所交易系统进 行网络投票的时间为2025年5月20日9:15—9:25，9:30—11:30和13:00—15:00；通过 深圳证券交易所互联网投票系统进行投票的具体时间为2025年5月20日9:15— ...

中国经济网北京5月16日讯维康药业（300878）(300878.SZ)日前披露的2024年年报显示，公司去年实现 营业收入3.51亿元，同比下降32.41%；归属于上市公司股东的净利润-1.47亿元，上年同期为-895.43万 元；归属于上市公司股东的扣除非经常性损益的净利润为-2.39亿元，上年同期为-2504.22万元；经营活 动产生的现金流量净额为-2717.30万元，上年同期为5828.91万元。 天健会计师事务所(特殊普通合伙)为公司出具了保留意见的审计报告。 维康药业2025年第一季度报告显示，公司首季实现营业收入6977.59万元，同比下降65.10%；归属于上 市公司股东的净利润-985.47万元，上年同期为2433.50万元；归属于上市公司股东的扣除非经常性损益 的净利润为-1054.48万元，上年同期为2003.24万元；经营活动产生的现金流量净额为-648.86万元，上年 同期为-1643.95万元。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | (%) | | 营业收入(元) | 69.775.93 ...

Group 1: Company Overview and Strategic Decisions - The company, Zhejiang Weikang Pharmaceutical Co., Ltd., focuses on modern Chinese medicine and Western medicine research, production, and sales [2] - The decision to sell Zhejiang Weikang Pharmaceutical Retail Co., Ltd. and Zhejiang Weikang Pharmacy Co., Ltd. aims to concentrate resources on pharmaceutical manufacturing [2] Group 2: Research and Development (R&D) Efforts - The company has established a comprehensive new drug R&D system, including market research and strict control at various stages of development [3] - As of the end of 2024, the company holds 37 drug approval numbers, with key products like Yinhuang Diban and Roxithromycin Soft Capsules having patents and core technologies [3] Group 3: Shareholder Returns - For the fiscal year 2024, the company plans to distribute a cash dividend of 1.4 yuan (after tax) for every 10 shares [3] - The company has a shareholder return plan for 2025-2027, committing to distribute at least 20% of the annual distributable profits in cash [3] Group 4: Future R&D Directions - The company will continue to develop innovative traditional Chinese medicine products and improve existing key products [4][5] - There is a focus on developing short-term projects with good market prospects, low investment, and shorter R&D cycles [5] Group 5: Industry Outlook - The company is optimistic about the future of the traditional Chinese medicine industry, supported by rising income levels, an aging population, and enhanced health awareness [5] - National policies are increasingly favoring the innovation and development of traditional Chinese medicine, contributing to the industry's vitality [5]

届时公司董事长兼总经理刘洋先生、董事会秘书朱婷女士、财务总监王静女 士、独立董事刘江峰先生将在线就公司 2024 年度业绩、公司治理、发展战略、 经营状况等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃 参与！ 特此公告。 证券代码：300878 证券简称：维康药业 公告编号：2025-022 浙江维康药业股份有限公司 关于参加 2025 年浙江辖区上市公司投资者网上集体接待日 暨 2024 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，浙江维康药业股份有限公司（以下简称 "公司"）将参加由浙江证监局指导，浙江上市公司协会主办，深圳市全景网络 有限公司承办的"2025 年浙江辖区上市公司投资者网上集体接待日暨 2024 年度 业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (https://rs.p5w.net)，或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2025 年 5 月 13 日(周二)15 ...

Core Viewpoint - Weikang Pharmaceutical reported a decline in revenue and net profit for 2024, with a focus on enhancing operational management and expanding its marketing network in 2025 [1][4] Financial Performance - In 2024, Weikang achieved revenue of 351 million yuan and a net profit of -147 million yuan; in Q1 2025, revenue was 69.78 million yuan with a net profit of -9.85 million yuan [1] - The company recorded non-recurring gains of 88.25 million yuan from the sale of its subsidiaries, while also accounting for fixed asset impairment losses of 76.20 million yuan [1] R&D and Innovation - Weikang emphasizes R&D and has established multiple research platforms, collaborating with industry experts and academic institutions [2] - The company is focusing on innovative drug development, with ongoing projects including two Class 1 traditional Chinese medicine (TCM) innovations and several Class 2 and Class 3 TCM new drugs [2] Product Highlights - The core product, Yinhuang Diban, has shown significant clinical effectiveness in treating various throat infections and has completed successful clinical trials for new indications [3] - Yinhuang Diban has received multiple accolades, including being ranked first in the retail terminal adult cold medication category in 2024 [3] Future Strategy - In 2025, Weikang plans to enhance its core business direction, improve operational management, and strengthen its marketing network to achieve performance targets [4] - The company aims to continue its focus on the health industry and cultivate new growth points aligned with its development strategy [4]

证券代码：300878 证券简称：维康药业 公告编号：2025-021 浙江维康药业股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 三、投资风险分析及风控措施 （一）投资风险分析 1、尽管公司投资理财业务均经过严格的评估，但金融市场受宏观经济的影 响较大，不排除该项投资受到市场波动的影响； 2、公司将根据经济形势以及金融市场的变化适时适量介入，因此短期投资 的实际收益不可预期； 浙江维康药业股份有限公司（以下简称"公司"）于 2024 年 10 月 25 日召 开第四届董事会第四次会议、第四届监事会第四次会议，审议通过了《关于使用 闲置自有资金进行委托理财的议案》，同意公司使用不超过人民币 5,000 万元闲 置自有资金进行委托理财，上述额度自董事会审议通过之日起 12 个月内有效， 在前述额度和期限范围内，可循环滚动使用。具体内容详见公司 2024 年 10 月 28 日披露于巨潮资讯网（http://www.cninfo.com.cn）的《关于使用闲置自有资金 进行委托理财的公告》（公告编号：202 ...